Loading...
Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations
LESSONS LEARNED. This single‐arm, phase II study shows that concurrent EGFR‐tyrosine kinase inhibitor plus thoracic radiotherapy as the first‐line treatment for stage IV non‐small cell lung cancer harboring EGFR active mutations provides long‐term control for the primary lung lesion, and 1‐year prog...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693693/ https://ncbi.nlm.nih.gov/pubmed/31040256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0285 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|